Europe's
Download
1 / 18

Thread of infectious diseases - high death toll - PowerPoint PPT Presentation


  • 2680 Views
  • Updated On :

Europe's Biotech deficit – consequences and hopes. ALEXANDER VON GABAIN . “ We cannot be a strong nation unless we are a healthy nation“. President Franklin D. Roosevelt. Thread of infectious diseases - high death toll, only part of the story. AT ANY TIME.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Thread of infectious diseases - high death toll' - flora


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Slide1 l.jpg

Europe's Biotech deficit – consequences and hopes

ALEXANDER VON GABAIN

“We cannot be a strong nation unless we are a healthy nation“

President Franklin D. Roosevelt


Thread of infectious diseases high death toll only part of the story l.jpg
Thread of infectious diseases - high death toll, only part of the story

  • AT ANY TIME

  • Every fourth human life terminated by microbial infections

  • 13 million deaths per year in developing countries only

  • 6 million children thereof

  • Multi-drug resistant microbes in hospitals and communities

  • Novel pathogens emerge

  • Bioterrorism

  • Pandemic flu, as seen 1918, with estimated 50 million deaths

  • Approx. 100 million people disabled by infectious diseases

  • 10 millions of children kept away from school due to infections

  • Infectious diseases deform, mutilate and disable children for life

  • DALY* is the greatest burden of infectious diseases

  • Economic burden cannot be calculated

* disability adjusted life years

FOPI-EFA-Symposium


Chronic infectious diseases a new paradigm in medicine l.jpg
Chronic infectious diseases - a new paradigm in medicine of the story

Are bacteria and viruses the cause of non- inhered diseases?

  • Autoimmune-diseases

  • Bacterial infections

  • Arteriosclerosis diseases

  • Neurodegenerative diseases

  • Viral infections

  • HPV, HCV, HBV, Helicobacter infections

  • Cancer

FOPI-EFA-Symposium


V accines a cost efficient success story l.jpg
V of the storyaccines - a cost - efficientsuccess story

FOPI-EFA-Symposium


The vaccine field challenges ahead and new paradigms l.jpg
The vaccine field: challenges ahead and new paradigms of the story

  • FORCES AT WORK

  • No efficacious vaccines against many infectious diseases

  • Many existing vaccines do not protect important population cohorts (e.g. influenza for elderly)

"Come back of

vaccines"

  • New vaccines open a wide field to prevent and to treat diseases with unmet need; e.g. HPV-induced cervix car-cinome, nicotine-dependence

  • Combination of therapeutic vaccines and other treatments open new therapeutics against chronic viral diseases and cancer

FOPI-EFA-Symposium


Growing market with a restricted number of mostly us prone vaccine players l.jpg

Industry Landscape of the story

% of market share

Growing market with a restricted number of mostly US-prone vaccine players

GLOBAL VACCINE MARKET

Traditional and combinations

US$ bn

Novel and therapeutic vaccines

21.9

16.6

11.7

  • Other

  • Sanofi-Aventis**

  • Novartis/

  • Chiron*

8.8

6.8

2.0

  • GSK

* recently acquired** strategic partners of Intercell

1990

2001

2003

2005E

2007E

2009E

Expected CAGR 2003 - 2009

  • Merck**

  • Global vaccine market 16%

  • Novel and therapeutic vaccines 38%

  • Traditional and combination 0% vaccines

  • Wyeth

Sources:Frost & Sullivan, Datamonitor, Theta Reports, Genesis, Company Information

Other: Acambis, Bavarian Nordic, Baxter, Intercell,Berna Biotech*, Corixa*, ID Biomedical*, Solvay

FOPI-EFA-Symposium


The innovation gap of the established pharma and vaccine industry a fact l.jpg
The innovation gap of the established pharma and vaccine industry - a fact

Number of new FDA approved drugs

  • bn US$

Pharma R&D spending

Source: Phar-maceutical Research and Manu-factures of America, FDA, Burill & Co.

FOPI-EFA-Symposium


Biotech industry provides hope majority of product pipeline comes from smaller biotech l.jpg
Biotech industry provides hope: majority of product pipeline comes from smaller biotech

COMPOUNDS IN DEVELOPMENT BY COMPANY SIZE

Others (mainly biotech)

Top 100 Pharma players

69%

Number of compounds

68%

67%

31%

55%

32%

33%

45%

Source: PharmaProjects, BCG

FOPI-EFA-Symposium


Europe s biotech vision or does history repeat l.jpg
Europe’s biotech vision or does history repeat? comes from smaller biotech

  • "In the following 10 years the Soviet Union will out-compete the capitalist economy of the USA in terms of per capita income, economic welfare, growth and high tech"

  • President Nikita Krushchev, 1963

"Until 2010 Europe will overtake the US in growth of Biotech industry“

EU Lisbon Summit, 2000

FOPI-EFA-Symposium


Sobering facts speak another language l.jpg
Sobering facts speak another language comes from smaller biotech

  • Europe

  • US

  • Public listed biotech companiesin percent

  • Private equity investment in biotechin % of GDP

  • Origin of patents used by European biotechin percent

  • <10

  • ~0.38

  • ~28

  • >30

  • ~1.50

  • ~52

FOPI-EFA-Symposium


Europe versus usa state of being behind l.jpg
Europe versus USA – state of being behind comes from smaller biotech

  • In US$ bn

  • Market cap (2005)

  • Revenue (2004)

Biotech Companies USA

  • Amgen

  • Genentech

  • Genzyme

  • 88.78

  • 87.86

  • 17.74

  • 10.55

  • 4.62

  • 2.20

  • Total

  • 194.38

  • 17.37

Biotech Companies Europe

  • Serono*

  • Actelion*

  • Quiagen*

  • 7.88

  • 1.98

  • 1.94

  • 2.46

  • 0.22

  • 0.96

  • Total

  • 11.80

  • 3.64

* not truly considered as Biotechs

FOPI-EFA-Symposium


Underdeveloped biotech consequences for biomedical research and health care l.jpg
Underdeveloped biotech - consequences for Biomedical Research and Health Care

  • Health care quality will drop: European hospitals become less and less R&D drivers (e.g. compare ratio of phase I/II to phase III/IV trials Europe versus USA)

  • Lack of job opportunities for MDs and PhDs in Europe

  • Brain drain – exodus of biomedical scientists (nearly 50% of European MD/Ph.D. scientists decide to stay in the USA 1990, today more than 70%!)

  • Biomedical research obtains less overflow from charities

FOPI-EFA-Symposium


Slide13 l.jpg

History: Research and Health CareSpin off from the Campus Vienna Biocenter, IMP and University 1999. Today 160 employees from 16 nations in Vienna, Edinburgh & North Carolina, USA

Partners:Merck (USA), Sanofi Aventis, SSI, Boehringer Ingelheim, SciGen, Biological E, EC, NIH, CDC, WRAIR, Karolinska, MPI, AERAS foundation

Funding:Investors include Apax, Nomura, TVM, MPM Capital, GLSV, Sal. Oppenheim & K&W. Since 2005 listed at the ATX (ICLL): Today’s Market cap: approx. € 300m

Products: Therapeutic & prophylactic vaccines based on the latest stage immunology and vaccine technology

Intercell, an international biotech vaccine player, a spin off from a Viennese University Chair

People:» Management board: G. Zettlmeissl (CEO), A. v. Gabain (CSO and founder) & W. Lanthaler (CFO)

» Supervisory board: E.G. Afting, D. Ebsworth, M. Gréco, H. Küpper,

H. Schühsler & J. Sulat

» SAB: R. Ahmed, H. Blum, S. Cohen, F.X. Heinz,

S. Kaufmann, S. Normark, H. Wigzell

FOPI-EFA-Symposium


Advanced clinical programs promising product pipeline and strategic partnerships l.jpg

  • 2006

  • Hepatitis C therapeutic (IC41)

  • 2008

  • 2011

*

**

***

****

  • S. pneumoniae

  • 2006/07

  • Group A Streptococcus

  • 2006/07

Advanced clinical programs – promising product pipeline and strategic partnerships

  • PRODUCT CANDIDATES OVERVIEW

Clinical progressin last 12 month

  • Pre-clinical

  • Phase I

  • Phase II

  • Phase III

  • Filing

  • Advanced clinical product candidates

  • Product

  • Pipeline

  • Therapeutic Antibodies

    S. pneumoniae; GBS

  • 2006

  • 2007

  • Travelers diarrhea

  • Tuberculosis*

  • 2006/07

  • Strategic partner-

  • ships

  • 2006

  • Hepatitis B therapeutic**

  • S. aureus***

  • 2006/07

  • Bacterial vaccine ****

  • 2006/07

FOPI-EFA-Symposium


European assets to build a robust biotech industry l.jpg
European assets to build a robust biotech industry Research and Health Care

  • High level of education

  • Solid academic base

  • Competent and good quality research at many Universities

  • Historical power-houses of research; Pasteur, Karolinska, Cambridge, Oxford, EMBO, Max Plank Institute, Basle Biozentrum, Campus Vienna Biocenter (Max Perutz lab., IMP IMBA) etc.

  • Growing number of Centers of Excellence

  • Long tradition of Pharma development

  • Excellent clinical institutions with the potential to carry out clinical research-driven studies

  • Growing interaction between the national biomedical scenes

  • Scientific output in the field of biotech is still significant

still European biotech hasn’t hit the street

FOPI-EFA-Symposium


Thank you for your attention l.jpg
Thank Research and Health Care you for your attention

If you think research isexpensive, try disease

Mary Lasker (1901-1994)

FOPI-EFA-Symposium


Slide17 l.jpg

For more information be invited to: www.intercell. Research and Health Carecom

FOPI-EFA-Symposium


Slide18 l.jpg

  • Doses of influenza vaccine distributed per 1,000 population

  • Canada

  • United States

  • Rep. of Korea

  • Australia

  • Spain

  • Belgium

  • The Netherlands

  • United Kingdom

  • Germany

  • New Zealand

  • Italy

  • Iceland

  • France

  • Japan

  • Switzerland

  • Greece

  • Finland

  • Ireland

  • Russia

  • Hungary

  • Portugal

  • Sweden

  • Denmark

  • Austria

  • Luxembourg

  • Slovak Republic

  • Slovenia

  • Norway

  • Argentina

  • Brazil

  • Poland

  • Latvia

  • Czech Republic

  • Romania

  • Lithuania

  • Bulgaria

  • South Africa

  • Mexico

  • Turkey

  • Egypt

Source: Journal of Public Health Policy

FOPI-EFA-Symposium


ad